行情

GLPG

GLPG

Galapagos
NASDAQ

实时行情|Nasdaq Last Sale

182.22
-8.53
-4.47%
交易中 14:43 08/10 EDT
开盘
185.13
昨收
190.75
最高
185.79
最低
181.16
成交量
8.98万
成交额
--
52周最高
274.03
52周最低
112.00
市值
118.91亿
市盈率(TTM)
103.98
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测GLPG价格均价为222.88,最高价位302.00,最低价为150.00。

EPS

GLPG 新闻

更多
Galapagos reports 1H results
Galapagos (NASDAQ:GLPG): 1H GAAP EPS of -€2.55. Revenues and other income of €224.6M (+107.0% Y/Y) Press Release
seekingalpha · 3天前
Galapagos reports solid H1 2020 progress
* First half-year 2020 financial results: * Group revenues and other income of €224.6 million * Operating loss of €130.8 million * Net loss of €165.6 million * Cash and current financial investments on 30 June 2020 of €5.6 billion * Positive CHMP
GlobeNewswire · 3天前
3 Biotech Stocks With Big Incoming Catalysts
MotleyFool.com · 07/25 04:00
European advisory group backs Gilead/Galapagos' filgotinib for rheumatoid arthritis
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Gilead Sciences (NASDAQ:GILD) and collaboration
seekingalpha · 07/24 17:33
GILEAD  AND  GALAPAGOS  ANNOUNCE  POSITIVE  EUROPEAN  CHMP  OPINION  FOR  JYSELECA®  (FILGOTINIB)  FOR  THE  TREATMENT  OF  ADULTS  WITH  MODERATE  TO  SEVERE  RHEUMATOID  ARTHRITIS
\-- Clinical Development Program of Filgotinib Demonstrated Durable Efficacy Balanced with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks -- Foster City, Calif., and Mechelen, Belgium, July 24 2020, 14:10 CET; regulated information – Gil
GlobeNewswire · 07/24 12:14
Gilead, Galapagos Report Positive CHMP Opinion for Jyseleca For Treatment Of Adults With Moderate To Severe Rheumatoid Arthritis
Benzinga · 07/24 12:11
European stocks close lower as U.S.-China tensions weigh on sentiment; Centrica up 16%
European markets closed lower on Friday as escalating diplomatic tensions between the world's two largest economies continued to weigh on sentiment.
CNBC.com · 07/24 06:15
Morgan Stanley Maintains Equal-Weight on Galapagos, Lowers Price Target to $224
Morgan Stanley maintains Galapagos (NASDAQ:GLPG) with a Equal-Weight and lowers the price target from $226 to $224.
Benzinga · 07/15 14:28

所属板块

生物技术和医学研究
+0.01%
制药与医学研究
-0.02%

热门股票

代码
价格
涨跌幅

GLPG 简况

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.
展开

微牛提供Galapagos NV(NASDAQ-GLPG)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的GLPG股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易GLPG股票基本功能。